Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 186 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Galderma R&D Clear all
Recruiting No phase listed Observational

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

NCT06988618
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Not listed
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

NCT02189629
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 (trifarotene)
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Rogers, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris

NCT00441415
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene BPO
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Santa Monica, California • Fridley, Minnesota • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash

NCT01892410
View directory record Official record
Conditions
Skin Irritation
Interventions
Cetaphil Restoraderm Skin Restoring Body Wash
Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50

NCT01887860
View directory record Official record
Conditions
Skin Irritation
Interventions
Cetaphil Daily Facial Moisturizer SPF 50
Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 1, 2026, 10:27 PM EDT
Active, not recruiting Not applicable Interventional

Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin

NCT06195605
View directory record Official record
Conditions
Photoaging
Interventions
Restylane-L, Vehicle
Device
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands

NCT04080882
View directory record Official record
Conditions
Platysmal Bands
Interventions
AbobotulinumtoxinA dose 1, Placebo, AbobotulinumtoxinA dose 2, AbobotulinumtoxinA dose 3
Biological · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Encinitas, California • Encino, California • Boynton Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparative Ultrasound Analysis of Two Hyaluronic Acid Dermal Fillers

NCT05622851
View directory record Official record
Conditions
Volume Deficiency of the Midface
Interventions
Restylane Contour, Juvederm Voluma
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Santa Rosa Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Active, not recruiting Phase 2 Interventional

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

NCT07074977
View directory record Official record
Conditions
Chronic Pruritus of Unknown Origin
Interventions
nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Restylane® Lyft Filler Injection for Hand Rejuvenation on First Impressions

NCT04162002
View directory record Official record
Conditions
Hand Rejuvination
Interventions
Restylane® Lyft
Drug
Lead sponsor
DeNova Research
Other
Eligibility
28 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia

NCT02460497
View directory record Official record
Conditions
Female Pattern Hair Loss, Androgenic Alopecia
Interventions
Treatment: Minoxidil 2% / Botanical Hair Solution for Women
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

NCT00599521
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene lotion 0.1%, Adapalene Lotion Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
San Diego, California • Vista, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 1, 2026, 10:27 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

NCT03989206
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
136
States / cities
Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01355458
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Clinton Township, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 1, 2026, 10:27 PM EDT
Not yet recruiting Phase 4 Interventional

Impact of Dysport on PMFF Donor Scar

NCT07720726
View directory record Official record
Conditions
Skin Cancer Excision Site, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
Interventions
Abobotulinumtoxin-A, Control- Saline injection
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes

NCT00907101
View directory record Official record
Conditions
P Acnes Colonization
Interventions
Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

NCT05146999
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
QM1114-DP, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
9
States / cities
Homewood, Alabama • Manhattan Beach, California • Vista, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

Restylane Defyne in a Stepwise Treatment Approach

NCT04520997
View directory record Official record
Conditions
Lower Face Folds and Lines
Interventions
Restylane Defyne
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

NCT02125279
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcitriol
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Burbank, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01318733
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel 0.5%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Santa Monica, California • Denver, Colorado • Longmont, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 1, 2026, 10:27 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
MAL Cream, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

NCT02932267
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene 0.3% / BPO 2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

NCT01046396
View directory record Official record
Conditions
Skin Manifestations
Interventions
adapalene cream 0.1% and adapalene lotion 0.1%, adapalene lotion 0.1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01174030
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 Gel, Vehicle Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Hot Springs, Arkansas • San Francisco, California • Newnan, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 1, 2026, 10:27 PM EDT